151 related articles for article (PubMed ID: 14534880)
21. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
23. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
24. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
Banu E; Banu A; Medioni J; Levy E; Thiounn N; Mejean A; Andrieu JM; Oudard S
Prostate; 2007 Oct; 67(14):1543-9. PubMed ID: 17705243
[TBL] [Abstract][Full Text] [Related]
25. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
[TBL] [Abstract][Full Text] [Related]
26. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
Eklund J; Kozloff M; Vlamakis J; Starr A; Mariott M; Gallot L; Jovanovic B; Schilder L; Robin E; Pins M; Bergan RC
Cancer; 2006 Jun; 106(11):2459-65. PubMed ID: 16615097
[TBL] [Abstract][Full Text] [Related]
28. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
Amin A; Halabi S; Gelmann EP; Stadler W; Vogelzang N; Small E
Urol Oncol; 2004; 22(5):398-403. PubMed ID: 15464920
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
Miyake H; Hara I; Yamazaki H; Eto H
Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
[TBL] [Abstract][Full Text] [Related]
31. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
Nakabayashi M; Xie W; Regan MM; Jackman DM; Kantoff PW; Oh WK
Cancer; 2006 Sep; 107(5):975-81. PubMed ID: 16862573
[TBL] [Abstract][Full Text] [Related]
32. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
Morris MJ; Smaletz O; Solit D; Kelly WK; Slovin S; Flombaum C; Curley T; Delacruz A; Schwartz L; Fleisher M; Zhu A; Diani M; Fallon M; Scher HI
Cancer; 2004 May; 100(9):1868-75. PubMed ID: 15112267
[TBL] [Abstract][Full Text] [Related]
33. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
Stathopoulos GP; Koutantos J; Vaslamatzis MM; Athanasiadis A; Papadopoulos G; Labrodimou G; Stathopoulos J; Rigatos S
Oncol Rep; 2009 Aug; 22(2):345-8. PubMed ID: 19578775
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.
Trump DL; Potter DM; Muindi J; Brufsky A; Johnson CS
Cancer; 2006 May; 106(10):2136-42. PubMed ID: 16598750
[TBL] [Abstract][Full Text] [Related]
37. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
Chan JS; Beer TM; Quinn DI; Pinski JK; Garzotto M; Sokoloff M; Dehaze DR; Ryan CW
BJU Int; 2008 Dec; 102(11):1601-6. PubMed ID: 18782306
[TBL] [Abstract][Full Text] [Related]
39. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
Rozhansky F; Chen MH; Cox MC; Dahut W; Figg WD; D'Amico AV
Cancer; 2006 Jan; 106(1):63-7. PubMed ID: 16333854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]